KORU Medical is a mechanical home-infusion franchise whose latest quarter finally showed a GAAP profit after years of losses. The equity still trades near $3.22, close to the yearly low, because the growth story just shed its first named oncology attachment. The debate is whether the Freedom syringe platform is a self-funding recurring-consumable compounder, or whether the August guidance narrowing and the Phesgo withdrawal mark the moment the adjacent-market narrative ran out of road.
Adam Kalbermatten's first quarter as chief executive delivered record net revenue of $12 million. Growth ran in the high teens, with domestic core still carrying most of the mix and international core jumping on prefilled-syringe stocking. Gross margin reached sixty-five percent on lower manufacturing cost and higher average selling prices. Adjusted earnings before interest, taxes, depreciation, and amortization, a cash-earnings proxy that adds back stock pay and strips interest, printed just under $1 million. That is the operating evidence that the installed patient base, now about sixty thousand chronic immunoglobulin users, can throw off cash once volume covers a relatively fixed commercial engine. The mechanism is classic razor-and-blade economics: pumps seed the account, then High-Flo needles and Precision tubing recur with every infusion.
The tension sits in what management itself pulled back. Full-year revenue guidance narrowed to a band around $48 million after European prefilled-syringe launches slipped. The company withdrew the FreedomEDGE filing for use with Phesgo, Roche's subcutaneous breast-cancer combination, in favor of unnamed higher-volume molecules. International core grew at a near-sixty-percent clip in the quarter, a rate that management already describes as set to moderate, which means the print that looks like a breakout may contain a distributor inventory pulse. A first-time GAAP profit of $0.3 million also sat beside a disposal loss of similar size on manufacturing assets, so the quality of the inflection is thinner than the headline.
What resolves the case over the next several quarters is whether domestic new-patient starts keep the core growing in the low teens while international conversions resume after the European timing pause, and whether gross margin holds above the raised full-year band once mix normalizes. The connected-monitoring asset bought in the quarter is a multiyear build, not a near-term earnings lever. If those two volume variables stall, the multiple already sitting near the yearly floor still has room to compress because the franchise has not yet proven it can grow without a European stocking spike or a named oncology win.